Wu G, Chen B, Jiang J, Chen Y, Chen Y, Wang H. Identification of a pyroptosis-based model for predicting clinical outcomes from immunotherapy in patients with metastatic melanoma. Cancer Med. 2023;12:4921–37.

Article  PubMed  Google Scholar 

Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12–49.

PubMed  Google Scholar 

Sun R, Wei S, Yu Y, Wang Z, Yao T, Zhang Y, et al. Prognostic value and immune infiltration of a tumor microenvironment-related PTPN6 in metastatic melanoma. Cancer Cell Int. 2024;24:435.

Article  PubMed  PubMed Central  Google Scholar 

Stachyra-Strawa P, Ciesielka M, Janiszewski M, Grzybowska-Szatkowska L. The role of immunotherapy and molecular‑targeted therapy in the treatment of melanoma (Review). Oncol Rep. 2021;46:158. https://doi.org/10.3892/or.2021.8109.

Article  PubMed  Google Scholar 

Lee SH, Song SY. Recent advancement in diagnosis of biliary tract cancer through pathological and molecular classifications. Cancers (Basel). 2024;16:1761.

Article  PubMed  Google Scholar 

Seedor RS, Orloff M. Treatment of metastatic melanoma in the elderly. Curr Oncol Rep. 2022;24:825–33.

Article  PubMed  Google Scholar 

Eddy K, Chen S. Overcoming immune evasion in melanoma. Int J Mol Sci. 2020;21:8984.

Article  PubMed  PubMed Central  Google Scholar 

Massand S, Neves RI. Emerging therapies in the treatment of advanced melanoma. Clin Plast Surg. 2021;48:713–33.

Article  PubMed  Google Scholar 

Tuli HS, Sak K, Iqubal A, Choudhary R, Adhikary S, Kaur G, et al. Recent advances in immunotherapy for the treatment of malignant melanoma. Curr Pharm Des. 2022;28:2363–74.

Article  PubMed  Google Scholar 

Teixido C, Castillo P, Martinez-Vila C, Arance A, Alos L. Molecular markers and targets in melanoma. Cells. 2021;10:2320.

Article  PubMed  PubMed Central  Google Scholar 

Đorđević Brlek Z, Jurakić Tončić R, Radoš J, Marinović B. Dermoscopy of nodular melanoma: review of the literature and report of 3 cases. Acta Dermatovenerol Croat. 2016;24:203–8.

PubMed  Google Scholar 

Hendrickx A, Cozzio A, Plasswilm L, Panje CM. Radiotherapy for lentigo maligna and lentigo maligna melanoma - a systematic review. Radiat Oncol. 2020;15:174.

Article  PubMed  PubMed Central  Google Scholar 

Goydos JS, Shoen SL. Acral lentiginous melanoma. Cancer Treat Res. 2016;167:321–9. https://doi.org/10.1007/978-3-319-22539-5_14.

Article  PubMed  Google Scholar 

Nicolson NG, Han D. Desmoplastic melanoma. J Surg Oncol. 2019;119:208–15. https://doi.org/10.1002/jso.25317.

Article  PubMed  Google Scholar 

Brown A, Sawyer JD, Neumeister MW. Spitz nevus: review and update. Clin Plast Surg. 2021;48:677–86. https://doi.org/10.1016/j.cps.2021.06.002.

Article  PubMed  Google Scholar 

Greenberg ES, Chong KK, Huynh KT, Tanaka R, Hoon DS. Epigenetic biomarkers in skin cancer. Cancer Lett. 2014;342:170–7. https://doi.org/10.1016/j.canlet.2012.01.020.

Article  PubMed  Google Scholar 

Amarillo D, Flaherty KT, Sullivan RJ. Targeted therapy innovations for melanoma. Hematol Oncol Clin North Am. 2024;38:973–95.

Article  PubMed  Google Scholar 

Namikawa K, Yamazaki N. Targeted therapy and immunotherapy for melanoma in Japan. Curr Treat Options Oncol. 2019;20:7.

Article  PubMed  PubMed Central  Google Scholar 

Miao Y, Quinn TP. Advances in receptor-targeted radiolabeled peptides for melanoma imaging and therapy. J Nucl Med. 2021;62:313–8.

Article  PubMed  PubMed Central  Google Scholar 

McKenna S, García-Gutiérrez L. Resistance to targeted therapy and RASSF1A loss in melanoma: what are we missing?. Int J Mol Sci. 2021;22:5115.

Article  PubMed  PubMed Central  Google Scholar 

Kozyra P, Pitucha M. Revisiting the role of B-RAF kinase as a therapeutic target in melanoma. Curr Med Chem. 2024;31:2003–20. https://doi.org/10.2174/0109298673258495231011065225.

Article  PubMed  Google Scholar 

Hashem O, Shahin AI, Al Hindawi MA, Fageeri MF, Al-Sbbagh SA, Tarazi H, et al. An overview of RAF kinases and their inhibitors (2019-23). Eur J Med Chem. 2024;275:116631. https://doi.org/10.1016/j.ejmech.2024.116631.

Article  PubMed  Google Scholar 

Gao XM, Li J, Cao XX. Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis. Cell Commun Signal. 2022;20:195.

Article  PubMed  PubMed Central  Google Scholar 

Lemech C, Arkenau HT. Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol. 2012;6:53–66.

Article  PubMed  PubMed Central  Google Scholar 

Ullah R, Yin Q, Snell AH, Wan L. RAF-MEK-ERK pathway in cancer evolution and treatment. Semin Cancer Biol. 2022;85:123–54.

Article  PubMed  Google Scholar 

Wang J, Sarkar A, Garcia N, Zhang L, Calizo A, Lisok A, et al. Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors. Mol Med. 2025;31:303.

Article  PubMed  PubMed Central  Google Scholar 

Su W, Mukherjee R, Yaeger R, Son J, Xu J, Na N, et al. ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. Mol Cell. 2022;82:2443–57.e7.

Article  PubMed  PubMed Central  Google Scholar 

Ta L, Tsai BL, Deng W, Sha J, Varuzhanyan G, Tran W, et al. Wild-type C-Raf gene dosage and dimerization drive prostate cancer metastasis. iScience. 2023;26:108480. https://doi.org/10.1016/j.isci.2023.108480.

Article  PubMed  PubMed Central  Google Scholar 

Wang P, Laster K, Jia X, Dong Z, Liu K. Targeting CRAF kinase in anti-cancer therapy: progress and opportunities. Mol Cancer. 2023;22:208.

Article  PubMed  PubMed Central  Google Scholar 

Venkatanarayan A, Liang J, Yen I, Shanahan F, Haley B, Phu L, et al. CRAF dimerization with ARAF regulates KRAS-driven tumor growth. Cell Rep. 2022;38:110351.

Article  PubMed  Google Scholar 

Brummer T, McInnes C. RAF kinase dimerization: implications for drug discovery and clinical outcomes. Oncogene. 2020;39:4155–69.

Article  PubMed  Google Scholar 

Yaeger R, Yao Z, Hyman DM, Hechtman JF, Vakiani E, Zhao H, et al. Mechanisms of acquired resistance to BRAF V600E inhibition in colon cancers converge on RAF dimerization and are sensitive to its inhibition. Cancer Res. 2017;77:6513–23.

Article  PubMed  PubMed Central  Google Scholar 

Jeon H, Tkacik E, Eck MJ. Signaling from RAS to RAF: the molecules and their mechanisms. Annu Rev Biochem. 2024;93:289–316.

Article  PubMed  Google Scholar 

Beneker CM, Rovoli M, Kontopidis G, Röring M, Galda S, Braun S, et al. Design and synthesis of type-IV inhibitors of BRAF kinase that block dimerization and overcome paradoxical MEK/ERK activation. J Med Chem. 2019;62:3886–97.

Article  PubMed  PubMed Central